Peking University Third Hospital
pku.edu.cnLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
724
Active
191
Phase 3
11
Total enrollment
666,630
Pipeline matrix
Showing 40 of 76 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Metformin | — | — | — | — | 3 | ||
| Tetrandrine | — | — | — | — | — | 2 | |
| Secukinumab | — | — | — | — | — | 1 | |
| SURGICEL® Powder | — | — | — | — | — | 1 | |
| allogeneic platelet plasma | — | — | — | — | — | 1 | |
| autologous platelet plasma | — | — | — | — | — | 1 | |
| Liraglutide and metformin | — | — | — | — | — | 1 | |
| Telitacicept | — | — | — | — | — | 1 | |
| Brivudine | — | — | — | — | — | 1 | |
| Famciclovir | — | — | — | — | — | 1 | |
| FB1006 | — | — | — | — | — | 1 | |
| Toripalimab | — | — | — | — | — | 2 | |
| Cisplatin | — | — | — | 4 | |||
| Carilizumab and Apatinib | — | — | — | — | — | 1 | |
| enfortumab vedotin | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Zimberelimab | — | — | — | — | — | 1 | |
| 9MW2821 | — | — | — | — | — | 1 | |
| Glofitamab | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Human Dental Fulp Stem Cells | — | — | — | — | — | 1 | |
| Treatment | — | — | — | — | — | 1 | |
| anti-CD19 CAR-T cells | — | — | — | — | — | 1 | |
| anti-CD19 CAR T cell therapy | — | — | — | — | — | 1 | |
| DCVAC/OvCa | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| GC019F | — | — | — | — | — | 1 | |
| SNUG01 | — | — | — | — | — | 1 | |
| BCT301 | — | — | — | — | — | 1 | |
| GLP-1 receptor agonist | — | — | — | — | — | 2 | |
| Nimotuzumab | — | — | — | — | 3 | ||
| Conservative management of ankylosing spondylitis | — | — | — | — | — | 1 | |
| Conservative management of lumbar spinal stenosis | — | — | — | — | — | 1 | |
| Suspective gene mutations and family history | — | — | — | — | — | 1 | |
| Budesonide irrigation | — | — | — | — | — | 1 | |
| Tumor Neoantigen-Sensitized Autologous Dendritic Cell | — | — | — | — | — | 1 | |
| total glucosides of paeony treatment | — | — | — | — | — | 1 | |
| Levofloxacin Plus Metronidazole Suppositories | — | — | — | — | — | 1 | |
| Levofloxacin co-administered with Metronidazole | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | — | 1 |
36 more active programs hidden
Next readouts
- 2023-12-15
- 2024-06-15
- 2024-10-20
- 2025-01-11
- 2025-03-07
- 2025-04-15
- 2025-07-31
- 2025-08
- 2025-09
- 2025-09
Top conditions
- Amyotrophic Lateral Sclerosis18
- Anterior Cruciate Ligament Injuries14
- Anterior Cruciate Ligament Rupture11
- Chronic Obstructive Pulmonary Disease11
- Lumbar Spinal Stenosis8
- Infertility, Female8
- Dry Eye8
- Stroke7
Frequently asked questions about Peking University Third Hospital
- How many clinical trials does Peking University Third Hospital have on ClinicalTrials.gov?
- Peking University Third Hospital is listed as the lead sponsor on 724 clinical trials in ClinicalTrials.gov, 191 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Peking University Third Hospital's trials are in Phase 3?
- 11 of Peking University Third Hospital's trials are in Phase 3, spread across 76 active drug programs.
- What therapeutic areas does Peking University Third Hospital focus on?
- Peking University Third Hospital's most-studied conditions on ClinicalTrials.gov are Amyotrophic Lateral Sclerosis, Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Chronic Obstructive Pulmonary Disease, Lumbar Spinal Stenosis.
- When are Peking University Third Hospital's next clinical trial readouts?
- Peking University Third Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL”, expected around 2023-12-15.